Table 5.

Time-dependent predictors of ExRA. Cox regression analysis. Values are HR (95% CI).

VariableBivariate AnalysisAnalysis Adjusted for Age and SexMultivariate Multivariate Analysis*Analysis*, Adjusted for Age and SexAnalysis Adjusted for Age, Sex, and Propensity Score**Multivariate Analysis*, Adjusted for Age, Sex, and Propensity Score**
All
  Anti-TNF treatment, time dependent1.10 (0.75–1.61)1.21 (1.02–1.43)1.17 (0.75–1.83)1.38 (0.83–2.27)1.25 (1.04–1.49)1.63 (0.94–2.83)
  HAQ, time dependent1.25 (0.81–1.94)1.45 (0.94–2.24)1.24 (0.78–1.99)1.29 (0.81–2.07)NDNA
RF-positive
  Anti-TNF treatment, time dependent1.00 (0.65–1.55)1.24 (1.03–1.48)1.01 (0.60–1.70)1.39 (0.79–2.44)1.40 (1.19–1.66)1.63 (0.91–2.91)
  HAQ, time dependent1.10 (0.65–1.86)1.31 (0.77–2.23)1.10 (0.62–1.92)1.18 (0.67–2.07)NDNA
RF-negative
  Anti-TNF treatment, time dependent2.38 (0.89–6.35)1.10 (0.66–1.82)1.24 (0.31–4.95)1.08 (0.25–4.69)1.18 (0.70–1.98)1.33 (0.28–6.40)
  HAQ, time dependent4.68 (1.84–11.86)4.58 (1.80–11.60)4.17 (1.28–13.60)4.39 (1.31–14.70)NDNA
  • * Includes both time-dependent predictors.

  • ** Propensity score for anti-TNF treatment based on age, sex, RA duration, first available HAQ, RF status, and treatment with methotrexate and glucocorticoids at baseline (RF status excluded in propensity scores for only RF-positive or -negative patients). RA: rheumatoid arthritis; ExRA: extraarticular RA; TNF: tumor necrosis factor; HAQ: Health Assessment Questionnaire; RF: rheumatoid factor; ND: not done; NA: not applicable.